{
    "SPADE_UN_18840": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_18840",
            "Peptide Name": "LL-37_Ranalexin hybrid peptide (LL-37_Renalexin, LL-37+GS+Ranalexin, synthetic AMPs)",
            "Source": "Hybrid peptide, designed",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESGSFLGGLIKIVPAMICAVTKKC",
            "Sequence Length": 59,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anti-MRSA"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 6725.09,
            "PI": 10.3,
            "Hydrophobicity": -0.0,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Narh JK, Casillas-Vega NG, Zarate X. 2024",
                    "Reference": "Appl Microbiol Biotechnol. 2024 Dec;108(1):126. doi: 10.1007/s00253-023-12887-5.PubMed",
                    "Title": "LL-37_Renalexin hybrid peptide exhibits antimicrobial activity at lower MICs than its counterpart single peptides."
                }
            ],
            "Frequent Amino Acids": "KIL",
            "Absent Amino Acids": "HOUWY",
            "Basic Residues": 14,
            "Acidic Residues": 5,
            "Hydrophobic Residues": 26,
            "Polar Residues": 29,
            "Positive Residues": 14,
            "Negative Residues": 5,
            "Net Charge": 9,
            "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (62.71%) toLL-37A hybrid peptide consisting of full length LL-37 and ranalexin are connected via a GS linker.Activity: active against S. aureus MRSA (MIC 17.5-20.1 uM), E. coli (MIC 19.7-21.4 uM), and K. pneumoniae (MIC 27.8 uM) bacteria clinical isolates.Recombinant production:bacteria:Escherichia coli: expressed as a fusion with small metal-binding proteins SmbP or CusF3H+.  cleaved with enzyme enterokinase, Purified via immobilized metal affinity chromatography, yield: 0.7-2.1 mg/L after affinity column.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_03107",
                    "Similarity": 1.0,
                    "Sequence": "ALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES"
                },
                {
                    "SPADE_ID": "SPADE_N_03128",
                    "Similarity": 1.0,
                    "Sequence": "LLGDFFRKSKEKIGKEFKRIVQR"
                },
                {
                    "SPADE_ID": "SPADE_N_03129",
                    "Similarity": 1.0,
                    "Sequence": "FALLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES"
                }
            ]
        }
    }
}